Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRevance Therapeu Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Revance Therapeu Earnings Date And Information
Revance Therapeu last posted its earnings results on Wednesday, February 26th, 2025. The company reported $-0.62 earnings per share for the quarter, missing analysts' consensus estimates of $-0.29 by $0.33. The company had revenue of 59.88 M for the quarter and had revenue of 234.04 M for the year. Revance Therapeu has generated $-4 earnings per share over the last year ($-3.83 diluted earnings per share) and currently has a price-to-earnings ratio of -0.95. Revance Therapeu has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Revance Therapeu Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.35 | -$0.34 | 0.01 | $68.17 M | $59.88 M |
| 08/08/2024 | Q2 2024 | -$0.48 | -$0.36 | 0.12 | $66.30 M | $65.39 M |
| 05/09/2024 | Q1 2024 | -$0.66 | -$0.58 | 0.08 | N/A | $51.94 M |
| 12/30/2023 | Q4 2023 | N/A | -$0.62 | N/A | N/A | $69.80 M |
| 11/08/2023 | Q3 2023 | -$1.02 | -$1.63 | -0.61 | $58.40 M | $56.78 M |
| 08/08/2023 | Q2 2023 | -$0.72 | -$0.80 | -0.08 | $58.71 M | $58.13 M |
| 05/09/2023 | Q1 2023 | -$0.75 | -$0.81 | -0.06 | $46.21 M | $49.33 M |
| 02/28/2023 | Q4 2022 | -$1.04 | -$1.80 | -0.76 | $44.95 M | $49.92 M |
| 11/08/2022 | Q3 2022 | -$0.85 | -$1.17 | -0.32 | $28.24 M | $29.02 M |
| 08/09/2022 | Q2 2022 | -$0.91 | -$0.88 | 0.03 | $28.15 M | $28.37 M |
| 05/10/2022 | Q1 2022 | -$0.91 | -$0.94 | -0.03 | $23.76 M | $25.26 M |
| 02/28/2022 | Q4 2021 | -$0.98 | -$0.93 | 0.05 | $23.91 M | $25.95 M |
| 11/09/2021 | Q3 2021 | -$1.15 | -$1.10 | 0.05 | $20.07 M | $19.75 M |
| 08/05/2021 | Q2 2021 | -$1.14 | -$1.07 | 0.07 | $15.50 M | $18.80 M |
| 05/10/2021 | Q1 2021 | -$1.19 | -$1.08 | 0.11 | $10.42 M | $13.30 M |
| 02/25/2021 | Q4 2020 | N/A | -$1.24 | N/A | $9.08 M | $11.13 M |
| 11/09/2020 | Q3 2020 | -$1.09 | -$1.34 | -0.25 | $1.84 M | $3.84 M |
| 08/06/2020 | Q2 2020 | -$0.96 | -$1.12 | -0.16 | $508.13 K | $299.00 K |
| 05/07/2020 | Q1 2020 | -$0.91 | -$1.15 | -0.24 | $169.50 K | $58.00 K |
| 02/26/2020 | Q4 2019 | N/A | -$0.99 | N/A | $2.52 M | $89.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Revance Therapeu Earnings: FAQ's
The conference call for Revance Therapeu's latest earnings report can be listened to online.
The conference call transcript for Revance Therapeu's latest earnings report can be read online.
Revance Therapeu (:RVNC) has a recorded annual revenue of $234.04 M.
Revance Therapeu (:RVNC) has a recorded net income of $-323,986,000.Revance Therapeu has generated $-3.83 earnings per share over the last four quarters.
Revance Therapeu (:RVNC) has a price-to-earnings ratio of -0.95 and price/earnings-to-growth ratio is -0.01.